Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Rhea-AI Summary
Sight Sciences (Nasdaq: SGHT) announced clinical data presentations for its OMNI Surgical System and TearCare System at the 2026 ASCRS Annual Meeting in Washington, DC on April 11. According to the company, OMNI data show reduced long-term diurnal IOP fluctuations regardless of lens status, while TearCare data report early and sustained superiority over Restasis for tear film stability.
Presentations include TearCare oral and poster sessions on April 11 and an OMNI poster on longer-term diurnal IOP following canaloplasty and trabeculotomy; lead and presenting authors are named.
Positive
- None.
Negative
- None.
News Market Reaction – SGHT
On the day this news was published, SGHT declined 3.83%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $7M from the company's valuation, bringing the market cap to $186.32M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Pre-news context shows mixed peer moves: ARAY +17.25%, BSGM +39.91%, CVRX +7.01%, while ELMD -4.53% and MGRM -1.64%. Momentum scanner only flags LNSR moving down, suggesting SGHT’s setup was more stock-specific than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | Conference participation | Neutral | +2.5% | Announcement of Needham Healthcare Conference fireside chat and webcast access. |
| Mar 30 | Litigation outcome | Positive | -5.2% | Court order preserving willful infringement verdict and awarding over $34M plus royalties. |
| Mar 04 | Earnings & guidance | Neutral | -26.8% | Reported 2025 results and 2026 guidance with revenue down 3% but margins and expenses improved. |
| Feb 18 | Earnings date notice | Neutral | +4.0% | Scheduled Q4 and full-year 2025 results release and conference call details. |
| Jan 13 | Preliminary earnings | Negative | -7.8% | Preliminary 2025 revenue with dry eye weakness and cash usage disclosure ahead of audit. |
Recent news has produced mixed reactions, with some positive or neutral updates sold into while clearly negative financial trends drew selling pressure.
Over the last few months, Sight Sciences issued several key updates. Earnings on Mar 4, 2026 and preliminary results on Jan 13, 2026 showed modest growth but pressured dry eye revenue, both followed by share price declines. A favorable patent damages order on Mar 30, 2026 with more than $34M awarded also saw a negative reaction. In contrast, an earnings-date announcement on Feb 18, 2026 and the Needham Conference appearance coincided with modest gains. Today’s ASCRS clinical spotlight fits the pattern of news aimed at strengthening the clinical and commercial story.
Market Pulse Summary
This announcement highlights upcoming OMNI and TearCare data at the 2026 ASCRS meeting, emphasizing diurnal IOP control and tear film stability endpoints. In the past six months, Sight Sciences combined clinical story-building with updates on earnings, guidance, and patent litigation. Investors may focus on how these new data support broader adoption in glaucoma and dry eye, especially given earlier disclosures on revenue mix and cash levels around $92M.
Key Terms
diurnal iop fluctuations medical
tear film stability medical
tear break-up time (tbut) medical
dry eye disease (ded) medical
localized heat therapy (lht) medical
canaloplasty medical
trabeculotomy medical
poster presentation technical
AI-generated analysis. Not financial advice.
MENLO PARK, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that data on two of its proprietary glaucoma and dry eye technologies, the OMNI® Surgical System and the TearCare® System, will be presented at this year’s ASCRS Annual Meeting held in Washington, DC.
“We look forward to highlighting new clinical data on our interventional technologies at the 2026 ASCRS meeting, the largest annual meeting for anterior segment surgeons,” said Paul Badawi, CEO and co-founder of Sight Sciences. “The data reinforce the durability and versatility of OMNI by demonstrating significant reductions in long-term diurnal IOP fluctuations regardless of lens status, while new TearCare results underscore the strength of our technology and showcase its clinical benefit to demonstrate early and sustained superiority of TearCare over Restasis in achieving a clinically relevant change in tear film stability. Collectively, the strength and growing depth of our clinical portfolio supports broader eyecare provider adoption and differentiated positioning in our core markets. We are thankful to all our clinical collaborators for their work demonstrating and sharing the benefits of our interventional technologies.”
TearCare System Oral and Poster Presentations:
- Outcomes for Localized Heat Therapy (LHT) or Cyclosporine in Dry Eye Disease (DED) Signs and Symptoms by Baseline Severity, Saturday, April 11 at 3:45 PM ET, at the Walter E. Washington Convention Center – Level 2, 209B. Presenting author: Mina Farahani, MD
- Clinically Relevant Change in Tear Break-up Time (TBUT) with Localized Heat Therapy or Cyclosporine in Dry Eye Disease (DED) – poster presentation. Lead author: Yuna Rapoport, MD
OMNI Surgical System Poster Presentation:
- Longer-term Diurnal IOP (DIOP) Fluctuations Following Canaloplasty and Trabeculotomy (CT) with and without cataract surgery – poster presentation. Lead author: Mark Pyfer, MD
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System and OMNI® Edge Surgical System are implant-free, minimally invasive glaucoma surgery technologies indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.
Sight Sciences and TearCare are trademarks of Sight Sciences registered in the United States. OMNI, SION, SmartLids, and the Sight Sciences logo are trademarks of Sight Sciences registered in the United States, European Union and other territories.
All educational content of the ASCRS Annual Meeting is planned by its program committee, and ASCRS does not endorse, promote, approve, or recommend the use of any products, devices, or services.
© 2026 Sight Sciences. All rights reserved.
Forward-Looking Statements
This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with such safe harbor provisions. Any statements made in this press release or during the earnings call that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include, but are not limited to, statements concerning anticipated data presentation on our glaucoma and dry eye technologies, and beliefs regarding broader adoption of our technologies. These statements often include words such as "anticipate," "expect," “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our business, results of operations and financial condition and could cause actual results to differ materially from those expressed in the forward-looking statements. These statements are not guarantees of future performance or results. These forward-looking statements are subject to and involve numerous risks, uncertainties and assumptions, including those discussed under the caption “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, as may be updated from time to time in subsequent filings, and you should not place undue reliance on these statements. These cautionary statements are made only as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
Media contact:
pr@SightSciences.com
